Literature DB >> 11404191

Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern.

I Kumagai1, T Masuda, S -i. Sato, K Ishikawa.   

Abstract

We evaluated the immunoreactivity to monoclonal antibody for hepatocyte (Hep Par 1) and determined the cellular distribution of the antigen in hepatocellular carcinoma (HCC), based on the histopathological grade and histological pattern. The pathological material included 100 areas selected at random in 61 tissue sections from 12 autopsy livers with HCC. Immunoreactivity was classified into four categories; strongly positive (>90% of the area showed positive staining), moderately positive (5-90% of the area), weakly positive (<5% of the area), and negative (completely negative). All 19 (100%) well-differentiated, trabecular type HCC areas were strongly positive for Hep Par 1. Among 11 well-differentiated, pseudoglandular type HCC areas, 2 (18%) were strongly positive, 5 (46%) were moderately positive, 2 (18%) were weakly positive, and 2 (18%) were negative. Among 36 moderately differentiated, trabecular type HCC areas, 6 (17%) were strongly positive, 17 (47%) were moderately positive, 9 (25%) were weakly positive, and 4 (11%) were negative. None of the four moderately differentiated, pseudoglandular type HCC areas were strongly positive, 3 (75%) were moderately positive, 0 was weakly positive, and 1 (25%) was negative. Among 25 poorly differentiated, compact or trabecular type HCC areas, 15 (60%) were weakly positive and 10 (40%) were negative. All 5 (100%) undifferentiated HCC areas were negative for Hep Par 1. Our results indicate that immunoreactivity to Hep Par 1 in HCC decreases with reduced differentiation of the tumor, suggesting that Hep Par 1 monoclonal antibody is useful as a marker for the diagnosis and differentiation of HCCs.

Entities:  

Year:  2001        PMID: 11404191     DOI: 10.1016/s1386-6346(00)00147-9

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

1.  Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

Authors:  Hideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto
Journal:  J Gastroenterol       Date:  2011-07-09       Impact factor: 7.527

2.  DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor.

Authors:  Paola Mazzarelli; Paola Parrella; Davide Seripa; Emanuela Signori; Giuseppe Perrone; Carla Rabitti; Domenico Borzomati; Armando Gabbrielli; Maria Giovanna Matera; Carolina Gravina; Marco Caricato; Maria Luana Poeta; Monica Rinaldi; Sergio Valeri; Roberto Coppola; Vito Michele Fazio
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

3.  Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.

Authors:  David Mondada; Fredrik T Bosman; Charlotte Fontolliet; Walter K F Seelentag
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

4.  Role of Hepatocyte Paraffin 1 antigen in the course of colorectal carcinogenesis.

Authors:  Riham M Abu-Zeid; Rola M Farid
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

5.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

6.  Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosis.

Authors:  T P Thamboo; A Wee
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.